Key terms
About RIGL
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest RIGL news
Apr 26
7:53am ET
Piper Sandler Remains a Hold on Rigel (RIGL)
Apr 04
8:11am ET
Rigel Pharmaceuticals’ olutasidenib shows efficacy in published AML study
Mar 12
8:08am ET
Rigel Pharmaceuticals names Lisa Rojkjaer, M.D. as Chief Medical Officer
Mar 07
7:07am ET
Rigel Pharmaceuticals price target raised to $4 from $3 at Citi
Mar 07
1:02am ET
New Corporate Activity and Growth Risk for Rigel Pharmaceuticals – What’s the Latest?
Mar 06
6:28am ET
Buy Rating Affirmed for Rigel on Strong Financials and Strategic Expansion
Mar 05
4:04pm ET
Rigel Pharmaceuticals reports Q4 EPS 0c, consensus (3c)
Mar 05
7:05am ET
Options Volatility and Implied Earnings Moves Today, March 05, 2024
Feb 26
8:25am ET
Rigel Pharmaceuticals price target raised to $1.75 from $1.25 at B. Riley
Feb 22
11:06am ET
Buy Rating for Rigel: Strategic Acquisitions and Market Positioning Fuel Revenue Growth Potential
Feb 22
8:14am ET
Rigel Pharmaceuticals Expands Oncology Portfolio with Blueprint Deal
Feb 22
7:54am ET
Rigel Pharmaceuticals acquires U.S. rights to Gavreto
No recent press releases are available for RIGL
RIGL Financials
Key terms
Ad Feedback
RIGL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
RIGL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range